Compare KB & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KB | TEVA |
|---|---|---|
| Founded | 2008 | 1901 |
| Country | South Korea | Israel |
| Employees | 126 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | KB | TEVA |
|---|---|---|
| Price | $86.41 | $28.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $29.78 |
| AVG Volume (30 Days) | 134.3K | ★ 10.9M |
| Earning Date | 02-06-2026 | 01-28-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ 31.42 | N/A |
| EPS | ★ 10.70 | 0.62 |
| Revenue | $10,599,662,483.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $17.52 | $4.74 |
| Revenue Next Year | $2.13 | $0.48 |
| P/E Ratio | ★ $7.77 | $45.91 |
| Revenue Growth | ★ 5.94 | 0.02 |
| 52 Week Low | $46.38 | $12.47 |
| 52 Week High | $92.39 | $29.10 |
| Indicator | KB | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 80.42 |
| Support Level | $87.09 | $28.00 |
| Resistance Level | $88.98 | $26.96 |
| Average True Range (ATR) | 1.26 | 0.65 |
| MACD | 0.02 | 0.14 |
| Stochastic Oscillator | 56.24 | 89.59 |
KB Financial Group Inc. is a financial holding company in Korea. The company operations include Kookmin Bank, one of the commercial banks in Korea. The company's subsidiaries collectively engage in a broad range of businesses, including commercial banking, credit cards, asset management, non-life and life insurance, capital markets activities, and international banking and finance. The company's segments include the Banking business, Securities business, Non-life Insurance business, Credit card business, and Life Insurance business. The Group generates the majority of its revenue from the Banking business.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.